134 related articles for article (PubMed ID: 2406013)
1. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders.
Junghans RP; Waldmann TA; Landolfi NF; Avdalovic NM; Schneider WP; Queen C
Cancer Res; 1990 Mar; 50(5):1495-502. PubMed ID: 2406013
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.
Hartmann F; Horak EM; Garmestani K; Wu C; Brechbiel MW; Kozak RW; Tso J; Kosteiny SA; Gansow OA; Nelson DL
Cancer Res; 1994 Aug; 54(16):4362-70. PubMed ID: 8044783
[TBL] [Abstract][Full Text] [Related]
3. Humanized Mik beta 1, a humanized antibody to the IL-2 receptor beta-chain that acts synergistically with humanized anti-TAC.
Hakimi J; Ha VC; Lin P; Campbell E; Gately MK; Tsudo M; Payne PW; Waldmann TA; Grant AJ; Tsien WH
J Immunol; 1993 Jul; 151(2):1075-85. PubMed ID: 8335891
[TBL] [Abstract][Full Text] [Related]
4. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
5. The multichain interleukin-2 receptor: a target for immunotherapy of patients receiving allografts.
Waldmann TA; Goldman CK
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):45-53. PubMed ID: 2683757
[TBL] [Abstract][Full Text] [Related]
6. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
[TBL] [Abstract][Full Text] [Related]
7. 1992 Stohlman Memorial Lecture: targeting the IL-2 receptor.
Waldmann TA
Leukemia; 1993 Aug; 7 Suppl 2():S151-6. PubMed ID: 8361223
[TBL] [Abstract][Full Text] [Related]
8. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia.
Zhang M; Zhang Z; Garmestani K; Goldman CK; Ravetch JV; Brechbiel MW; Carrasquillo JA; Waldmann TA
Cancer Res; 2004 Aug; 64(16):5825-9. PubMed ID: 15313926
[TBL] [Abstract][Full Text] [Related]
9. IL-2 receptor expression in the haematologic malignancies: a target for immunotherapy.
Waldmann TA
Cancer Surv; 1989; 8(4):891-903. PubMed ID: 2701734
[TBL] [Abstract][Full Text] [Related]
10. Two mouse monoclonal antibodies detecting two different epitopes of an activated lymphocyte antigen on adult T-cell leukemia cells.
Ueda R; Nishida K; Koide Y; Tsuge I; Seto M; Yoshida M; Miyoshi I; Ota K; Takahashi T
Cancer Res; 1985 Mar; 45(3):1314-9. PubMed ID: 2578877
[TBL] [Abstract][Full Text] [Related]
11. Anti-IL-2 receptor monoclonal antibody (anti-Tac) treatment of T-cell lymphoma.
Waldmann TA
Important Adv Oncol; 1994; ():131-41. PubMed ID: 8206486
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 2 receptor (Tac antigen) expression in HTLV-I-associated adult T-cell leukemia.
Waldmann TA; Longo DL; Leonard WJ; Depper JM; Thompson CB; Krönke M; Goldman CK; Sharrow S; Bongiovanni K; Greene WC
Cancer Res; 1985 Sep; 45(9 Suppl):4559s-4562s. PubMed ID: 2990687
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2 receptor expression in retrovirus associated adult T-cell leukemia.
Waldmann TA; Leonard WJ; Depper JM; Krönke M; Goldman CK; Oh T; Greene WC
Princess Takamatsu Symp; 1984; 15():259-68. PubMed ID: 6100644
[TBL] [Abstract][Full Text] [Related]
14. Humanized antibody directed to the IL-2 receptor beta-chain prolongs primate cardiac allograft survival.
Tinubu SA; Hakimi J; Kondas JA; Bailon P; Familletti PC; Spence C; Crittenden MD; Parenteau GL; Dirbas FM; Tsudo M
J Immunol; 1994 Nov; 153(9):4330-8. PubMed ID: 7930631
[TBL] [Abstract][Full Text] [Related]
15. The anti-idiotypic response by cynomolgus monkeys to humanized anti-Tac is primarily directed to complementarity-determining regions H1, H2, and L3.
Schneider WP; Glaser SM; Kondas JA; Hakimi J
J Immunol; 1993 Apr; 150(7):3086-90. PubMed ID: 8454876
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells.
Uchiyama T; Hori T; Tsudo M; Wano Y; Umadome H; Tamori S; Yodoi J; Maeda M; Sawami H; Uchino H
J Clin Invest; 1985 Aug; 76(2):446-53. PubMed ID: 2993359
[TBL] [Abstract][Full Text] [Related]
17. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
18. Lymphokine receptor-directed therapy: a model of immune intervention.
Waldmann TA; Grant A; Tendler C; Greenberg S; Goldman C; Bamford R; Junghans RP; Nelson D
J Clin Immunol; 1990 Nov; 10(6 Suppl):19S-28S; discussion 28S-29S. PubMed ID: 2081786
[TBL] [Abstract][Full Text] [Related]
19. The role of the multichain IL-2 receptor complex in the control of normal and malignant T-cell proliferation.
Waldmann TA; Tsudo M
Prog Clin Biol Res; 1988; 262():283-93. PubMed ID: 2897696
[TBL] [Abstract][Full Text] [Related]
20. Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation.
Depper JM; Leonard WJ; Robb RJ; Waldmann TA; Greene WC
J Immunol; 1983 Aug; 131(2):690-6. PubMed ID: 6408186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
